T. Rowe Price Associates
IMUX icon

T. Rowe Price Associates’s Immunic IMUX Stock Holding History

T. Rowe Price Associates’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,238
Closed -$4.18M – 2938
2021
Q1 		$4.18M Sell
26,238
-15,210
-37% -$2.58M ﹤0.01% 1505
2020
Q4 		$6.34M Buy
+41,448
New +$7.44M ﹤0.01% 1415
2018
Q3 		– Sell
-2,040
Closed -$5.59M – 2593
2018
Q2 		$5.59M Buy
2,040
+637
+45% +$1.47M ﹤0.01% 1423
2018
Q1 		$3.81M Buy
+1,403
New +$3.22M ﹤0.01% 1461
2017
Q4 		– Sell
-44
Closed -$89K – 2589
2017
Q3 		$89K Hold
44
– – ﹤0.01% 2504
2017
Q2 		$51K Hold
44
– – ﹤0.01% 2527
2017
Q1 		$71K Hold
44
– – ﹤0.01% 2517
2016
Q4 		$77K Hold
44
– – ﹤0.01% 2494
2016
Q3 		$109K Sell
44
-1
-2% -$2.47K ﹤0.01% 2433
2016
Q2 		$111K Hold
45
– – ﹤0.01% 2411
2016
Q1 		$161K Buy
45
+1
+2% +$3.47K ﹤0.01% 2334
2015
Q4 		$204K Buy
+44
New +$144K ﹤0.01% 2297
2015
Q3 		– Sell
-3,200
Closed -$27M – 2526
2015
Q2 		$27M Buy
3,200
+2,124
+197% +$20.3M 0.01% 1055
2015
Q1 		$10.8M Buy
+1,076
New +$9.89M ﹤0.01% 1320

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's IMUX Position: Q2 2021 in Review

T. Rowe Price Associates sold out of Immunic (IMUX) in Q2 2021, closing a stake of 26,238 shares — an estimated $4.18M sold.

T. Rowe Price Associates first reported a position in IMUX in Q1 2015 and held it in 14 quarters. The position peaked at $27M in Q2 2015. 60 funds tracked by Wall St. Rank hold IMUX as of Q2 2021.

  • T. Rowe Price Associates reported no remaining Immunic position as of Q2 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 26,238 Immunic shares in Q2 2021, an estimated $4.18M.
  • T. Rowe Price Associates first reported a position in Immunic in Q1 2015 and held it in 14 quarters.
  • T. Rowe Price Associates's Immunic position peaked at $27M in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Immunic as of Q2 2021.

Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.